Patents by Inventor Rudolf NAPIERALSKI

Rudolf NAPIERALSKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for assessing the treatment response of TNBC patients to neo-adjuvant chemotherapy by analysing CpG methylation
    Patent number: 11230737
    Abstract: The present invention relates to methods for predicting the efficacy of anthracycline-based neo-adjuvant chemotherapy in triple-negative breast cancer. This is achieved by determining epigenetic changes within the PITX2 gene. Detection of the methylation state of Cp G sites in a genomic sequence of PITX2 allows an estimate of the response or failure of an individual breast cancer patient to neo-adjuvant therapy.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: January 25, 2022
    Inventors: Manfred Schmitt, Olaf G. Wilhelm, Rudolf Napieralski
  • A METHOD FOR PREDICTING A BREAST CANCER PATIENT'S RESPONSE TO ANTHRACYCLINE TREATMENT
    Publication number: 20200181712
    Abstract: The present invention relates to a method for predicting a breast cancer patient's response to anthracycline treatment.
    Type: Application
    Filed: May 19, 2017
    Publication date: June 11, 2020
    Inventors: Manfred Schmitt, Rudolf Napieralski, Elisabeth Schüren, Michaela Aubele, Magdalena Absmaier, Eva Gross, Tibor Schuster, Heinz Höfler, Marion Kiechle
  • METHODS FOR ASSESSING THE TREATMENT RESPONSE OF TNBC PATIENTS TO NEO-ADJUVANT CHEMOTHERAPY BY ANALYSING CPG METHYLATION
    Publication number: 20190323084
    Abstract: The present invention relates to methods for predicting the efficacy of anthracycline-based neo-adjuvant chemotherapy in triple-negative breast cancer. This is achieved by determining epigenetic changes within the PITX2 gene. Detection of the methylation state of Cp G sites in a genomic sequence of PITX2 allows an estimate of the response or failure of an individual breast cancer patient to neo-adjuvant therapy.
    Type: Application
    Filed: February 10, 2017
    Publication date: October 24, 2019
    Applicant: THERAWIS DIAGNOSTICS GMBH
    Inventors: Manfred SCHMITT, Olaf G. WILHELM, Rudolf NAPIERALSKI